IL28B genotype predicts response to chronic hepatitis C triple therapy with telaprevir or boceprevir in treatment naïve and treatment-experienced patients other than prior partial- and null-responders

SpringerPlus

Table 3 Multivariate logistic regression analysis of baseline characteristics significantly associated with SVR12 to triple therapy in the bivariate analysis

Variable	Association with SVR12 to triple therapy
Variable	OR	95% CI	P value
Gender female	1.4	0.42–4.50	0.594
Advanced liver fibrosis (METAVIR F3 or F4)	0.3	0.12–0.89	0.029
Partial or null-responders to previous HCV therapy	0.3	0.12–0.94	0.039
HCV genotype 1b	3.4	1.20–9.51	0.021
Baseline HCV viral load <800,000 IU/mL	3.0	0.89–10.22	0.076
IL28B rs12979860-CC	7.4	1.70–32.08	0.007